Table 1 Characteristics of the studied population and ovarian stimulation parameters according to the endometrial thickness
| Â | Group 1 | Group 2 | Total | Test | p-value (0.05) |
|---|---|---|---|---|---|
Variable | EMT < 7 mm (n = 15) | EMT ≥ 7 mm (n = 42) | (n = 57) | Not applicable | |
Age (years) | 33.7±1.5 (30–35) | 34.0±1.7 (29–39) | 33.9±1.6 (29–39) | z = 0.67 | 0.501 |
Basal FSH (mIU/ml) | 7.0±2.0 (2.1–9.7) | 7.1±1.8 (1.9–10.0) | 7.0±1.9 (1.9–10.0) | t = 0.21 | 0.836 |
Basal LH (mIU/ml) | 5.2±2.0 (1.4-9.0) | 5.1±1.8 (1.5-9.0) | 5.1±1.8 (1.4-9.0) | t = 0.21 | 0.834 |
Basal E2(pg/ml) | 46.6±20.9 (13–78) | 52.7±26.9 (16–130) | 51.1±25.4 (13–130) | t = 0.81 | 0.428 |
AMH ng/ml | 2.3±1.5 (1.2–6.3) | 2.7±2.2 (1.2–10.0) | 2.6±2.0 (1.2–10.0) | t = 0.69 | 0.497 |
AFC n. | 9.4±4.5 (5–19) | 10.6±4.1 (5–20) | 10.3±4.2 (5–20) | t = 0.94 | 0.351 |
BMI (kg/m2) | 22.3±1.5 (18.9–24.8) | 22.4±1.2 (19.8–24.4) | 22.3±1.4 (18.9–24.8) | t = 0.64 | 0.47 |
Stimulation duration (days) | 10.5±1.0 (9–13) | 10.8±0.9 (9–13) | 10.7±0.9 (9–13) | t = 1.17 | 0.245 |
Antagonist administration duration (days) | 4.1±0.7 (3–5) | 3.8±0.7 (3–5) | 3.9±0.7 (3–5) | t = 1.15 | 0.253 |
E2 at hCG-d (pg/ml) | 1371.4±671.8 (471–2368) | 1400.4±629.8 (425–2718) | 1392.8±635.1 (425–2718) | t = 0.15 | 0.881 |
P at hCG-d (ng/ml) | 0.91±0.23 (0.3–1.5) | 0.89±0.10 (0.3–1.5) | 0.9±0.09 (0.3–1.5) | t = 1.38 | 0.175 |